SCHEMBL6578485

SCHEMBL6578485

COc1cc2c(c3c1OC(C)(C)C3)C(c1cccc(-c3ccco3)c1)=NC(C)(C)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
HPGD P15428 4/20 0.36
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
TP53 P04637 3/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.32
SLC2A1 P11166 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
PRMT6 Q96LA8 1/20 0.32
BUB1 O43683 1/20 0.31
PDE4D Q08499 1/20 0.31
ERN1 O75460 1/20 0.31
NFKB1 P19838 1/20 0.31
MAPK1 P28482 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5788447 0.90 MEN1 (0.32) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL5784117 0.90 ALDH1A1 (0.39) KDM4EHPGDALDH1A1MEN1KMT2A
SCHEMBL5787614 0.87 KDM4E (0.38) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL5785611 0.86 KDM4E (0.36) KDM4EHPGDALDH1A1SMN1; SMN2TP53
SCHEMBL5785757 0.85 KDM4E (0.41) KDM4EHPGDALDH1A1SMN1; SMN2TP53
SCHEMBL5787698 0.85 KDM4E (0.35) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL5785307 0.85 KDM4E (0.35) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL5784476 0.84 LMNA (0.36) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL5783172 0.84 KDM4E (0.36) KDM4EHPGDALDH1A1KMT2ASMN1; SMN2
SCHEMBL5786854 0.84 MAPK10 (0.40) KDM4EHPGDALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof PDE3B, PDE5A, PDE3A KDM4E 300/4885HPGD 306/4885ALDH1A1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.